NeXstar Pharmaceuticals Inc. (NXTR), Supragen Inc. deal

NXTR signed a definitive agreement to acquire Supragen, a privately held developer of therapeutics and vaccines for T cell mediated diseases, for 753,425 shares. The deal is valued at $11 million. NXTR, which closed at $14.50 on Friday, has 23 million shares outstanding prior to the acquisition. ...